ArticleFrontiers in pharmacology2026
Nonpolysaccharide fraction of
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cyclophosphamide (CTX)-induced immunosuppression is closely associated with oxidative stress and ferroptosis, but effective therapeutic interventions remain limited. This study investigated the protective effects of the non-polysaccharide fraction of Methods: LJFE was prepared by water extraction followed by ethanol precipitation, and its chemical profile was characterized using UPLC-MS/MS. Mice with CTX-induced immunosuppression were administered LJFE at doses of 100, 200, and 400 mg/kg for 10 consecutive days. Immune organ indices, serum IgE and IgM levels, oxidative stress markers (SOD, GSH, MDA), and the TBX21/GATA3 ratio were measured. The Keap1/Nrf2/HO-1/GPX4 signalling pathway was investigated via Western blotting and immunofluorescence. Serum metabolomics and molecular docking were applied to screen key differential metabolites and predict binding interactions between characteristic components and target proteins. LPS-stimulated RAW264.7 macrophages were used to verify pathway activation. Results: Seventeen chemical constituents were identified in LJFE. Conclusion: LJFE ameliorates CTX-induced immunosuppression by modulating the Keap1/Nrf2/HO-1/GPX4 pathway, thereby alleviating oxidative stress and ferroptosis. These findings support the potential of LJFE for further development as an immune-enhancing functional food ingredient.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.